2024
Contemporary management of aneurysmal subarachnoid haemorrhage. An update for the intensivist
Robba C, Busl K, Claassen J, Diringer M, Helbok R, Park S, Rabinstein A, Treggiari M, Vergouwen M, Citerio G. Contemporary management of aneurysmal subarachnoid haemorrhage. An update for the intensivist. Intensive Care Medicine 2024, 50: 646-664. PMID: 38598130, PMCID: PMC11078858, DOI: 10.1007/s00134-024-07387-7.Peer-Reviewed Original ResearchConceptsIntensive care unitAneurysmal subarachnoid haemorrhageRuptured aneurysmsLong-term prognostic factorsRisk of rebleedingIntensive care unit managementRobust clinical evidenceDelayed cerebral ischaemiaExpert clinical experienceSecondary brain damageDeterminants of functional outcomePrognostic factorsASAH patientsPrompt diagnosisHaemodynamic monitoringClinical evidenceMorbidity rateSpecialized centersTreatment strategiesClinical trialsContemporary guidelinesPatient populationFunctional outcomesCare unitCerebral ischaemia
2016
Randomized Pilot Trial of Two Modified Endotracheal Tubes To Prevent Ventilator-associated Pneumonia
Deem S, Yanez D, Sissons-Ross L, Broeckel JA, Daniel S, Treggiari M. Randomized Pilot Trial of Two Modified Endotracheal Tubes To Prevent Ventilator-associated Pneumonia. Annals Of The American Thoracic Society 2016, 13: 72-80. PMID: 26523433, PMCID: PMC4722846, DOI: 10.1513/annalsats.201506-346oc.Peer-Reviewed Original ResearchConceptsEndotracheal tubeTracheal colonizationChest radiograph criteriaOccurrence of VAPPrevention of VAPCoprimary end pointsSerious adverse eventsInstitutional review board approvalEmergency endotracheal intubationStandard endotracheal tubeMajority of intubationsReview board approvalModified Endotracheal TubeSafety concernsAdverse eventsVAP preventionEndotracheal intubationSubglottic secretionsEmergency intubationClinical trialsClinical signsNosocomial infectionsPilot trialStudy groupHospital setting
2014
Assessment of Circulating Blood Volume with Fluid Administration Targeting Euvolemia or Hypervolemia
Joffe AM, Khandelwal N, Hallman MR, Treggiari MM. Assessment of Circulating Blood Volume with Fluid Administration Targeting Euvolemia or Hypervolemia. Neurocritical Care 2014, 22: 82-88. PMID: 25142828, DOI: 10.1007/s12028-014-9993-8.Peer-Reviewed Original ResearchConceptsSubgroup of patientsBlood volumeHV groupDay 5Fluid administrationFluid balanceDelayed ischemic neurologic deficitsCrystalloid fluid administrationIschemic neurologic deficitCumulative fluid balanceML/Higher fluid balanceT-testStudent's t-testProphylactic hypervolemiaICU admissionICU stayResultsTwenty patientsNeurologic deficitsCerebral vasospasmClinical trialsHypervolemiaNormovolemiaBVA-100Concurrent group
2013
Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis
Mayer‐Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch‐Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW, for the EPIC E. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatric Pulmonology 2013, 48: 943-953. PMID: 23818295, PMCID: PMC4059359, DOI: 10.1002/ppul.22693.Peer-Reviewed Original ResearchConceptsTobramycin inhalation solutionHistorical controlsCystic fibrosisTrial participantsCulture positivityPA recurrenceDifferent antibiotic regimensHistorical control cohortInitial eradication therapyIncidence of hospitalizationStandard of careAntibiotic regimensEradication therapyRespiratory symptomsStandard careHospitalization outcomesHospitalization ratesCare treatmentControl cohortInhalation solutionAntimicrobial therapyClinical trialsEpidemiologic studiesInfection controlEligibility criteria
2009
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,
Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, Group E. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,. Contemporary Clinical Trials 2009, 30: 256-268. PMID: 19470318, PMCID: PMC2783320, DOI: 10.1016/j.cct.2009.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAnti-Bacterial AgentsChildChild, PreschoolCiprofloxacinCohort StudiesCystic FibrosisDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansInfantLongitudinal StudiesMalePseudomonas aeruginosaPseudomonas InfectionsRisk FactorsTobramycinTreatment OutcomeConceptsEarly Pa infectionYoung CF patientsRespiratory culturesRisk factorsCystic fibrosisCohort studyPA infectionClinical trialsObservational studyCF patientsEarly CF lung diseaseProgressive obstructive pulmonary diseaseProportion of patientsClinical efficacy dataObstructive pulmonary diseasePositive respiratory culturesPatients ages 1Longitudinal cohort studyCF lung diseaseChronic endobronchial infectionInfection control programPa acquisitionPA-negative patientsOral ciprofloxacinOral placebo